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A B S T R A C T
We generated an induced pluripotent stem cell (iPSC) line from fibroblasts of a clinically diagnosed 70 year old female Parkinson's disease (PD) patient heterozygous
for a pathogenic missense variant (p.G2019S; c. 6055 G > A) in the leucine-rich repeat kinase 2 (LRRK2) gene by using non-integrating Sendai viruses. The DANi-
011A iPSC line has a normal karyotype and is free from Sendai viruses. The expression of pluripotent markers in the iPSC line was confirmed by immunofluorescent
staining, and we confirmed its ability to differentiate into the three germ layers. The DANi-011A iPSC line can be used for modeling PD and as a drug-screening
platform.
Resource table:
Unique stem cell line i-
dentifier
DANi-011A
Alternative name(s) of
stem cell line
LRRK2-011-C1
Institution Danish Research Institute of Translational Neuroscience
(DANDRITE), Aarhus, Denmark
Contact information of
distributor
Mark Denham, mden@dandrite.au.dk
Type of cell line iPSC
Origin Human
Additional origin info Age: (age of disease onset) 70
Sex: Female
Ethnicity if known: Unknown
Cell Source Skin fibroblasts
Clonality Clonal
Method of reprogram-
ming
Sendai Virus with POU5F1, SOX2, KLF4 and MYCL
Genetic Modification Yes
Type of Modification Hereditary
Associated disease Parkinson's disease
Gene/locus Gene LRRK2, Locus 12q12, Mutation NM_198,578.3:c.6055
G>A (NP_940,980.3:p.Gly2019Ser)
Method of modification Not applicable
Name of transgene or r-
esistance
Not applicable
Inducible/constitutive s-
ystem
Not applicable
Date archived/stock
date
Jan. 14, 2018
Cell line repository/
bank
https://hpscreg.eu/cell-line/DANi011-A
Ethical approval Ethics Committee at the Medical Faculty of Eberhard-Karls
University and at the University Hospital Tübingen: 199 /
2011BO1
1. Resource utility
LRRK2 mutations have been identified in both inherited and
sporadic cases of Parkinson's disease (PD), and the G2019S point mu-
tation is the most common pathogenic variant of LRRK2 across popu-
lations worldwide (Nichols et al., 2005; Paisán-Ruíz et al., 2004;
Zimprich et al., 2004). The established induced pluripotent stem cell
(iPSC) line, DANi-011A, can be used to study disease mechanisms as
well as in a drug-screening platform.
2. Resource details
LRRK2 mutations cause autosomal dominant PD (Paisán-Ruíz et al.,
2004; Zimprich et al., 2004); however, the penetrance varies con-
siderably among ethnic populations (Marder et al., 2015; Sierra et al.,
2011). The majority of G2019S LRRK2-associated PD patients display
comparable clinical symptoms and Lewy body pathology to that of
sporadic PD patients (Nichols et al., 2005). In this paper, we report the
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generation of an iPSC line DANi-011A, from a PD patient carrying the
LRRK2 p.G2019S (c.6055G>A) variant (Table 1). The fibroblasts were
reprogrammed using Sendai virus particles containing transcripts for
POU5F1, SOX2, KLF4 and MYCL. After four weeks, the appearance of
iPSC clones was observed. Subsequently, the clone LRRK2-011-C1
(DANi-011A) was picked and expanded on feeders for further char-
acterization. Chromosomal analysis showed a normal female karyotype,
46,XX (Fig. 1G). The LRRK2 p.G2019S (c.6055G>A) variant was con-
firmed in the patient fibroblasts and the iPSCs (Fig. 1E). The iPSCs
expressed the pluripotent markers, POU5F1, NANOG, SSEA4 and TRA-
1–81 and were alkaline phosphatase positive (Fig. 1A, C, D). Plur-
ipotency was quantified by counting the percentage of NANOG+/DAPI
and POU5F1+/DAPI cells from three different colonies (Fig. 1B).
DANi-011A was confirmed to be free from Sendai viral particles,
which was analyzed by immunostaining (Fig. 1F). The DANi-011A line
successfully formed embryoid bodies and neurospheres within which
we identified cell types representative of the three germ layers, in-
dicated by immunoreactivity for PAX6/SOX2 (ectoderm), BRACHYURY
(mesoderm) and SOX17/FOXA2 (endoderm) (Fig. 1H). The absence of
mycoplasma was confirmed by PCR (Supplementary Figure 1). The
genetic identity of DANi-011A matched the donor fibroblasts, which
was determined by a genetic profile of a set of STR loci.
3. Materials and methods
3.1. Reprogramming and maintenance of human iPSCs
The patient fibroblasts were obtained from the Neuro-Biobank of
the University of Tuebingen, Germany (http://www.hihtuebingen.de/
nd/biobank/for-researchers/) and expanded in RPMI medium supple-
mented with 1% glutamax, 0.5% pen/strep (both from Thermo Fisher),
10% FCS (Biowest) and FGF2 (10 ng/ml; Peprotech). Reprogramming
was performed on 100,000 cells, which were seeded on a 9.6 cm2 well
(6-well plate, Thermo Fisher) coated with Vitronetcin XF™ (STEMCELL
Technologies). After cells attached, they were infected with Sendai viral
particles, which together contained POU5F1, SOX2, KLF4 and MYCL
(CytoTune-iPS 2.0; Life Technologies), in TeSR™-E7™ medium (STEM-
CELL Technologies). The TeSR™-E7™ media was changed every
3–4 days. When iPSC colonies emerged, media was changed to TeSR™-
E8 ™ medium (STEMCELL Technologies). After a further 4–7 days, co-
lonies were manually picked and cultured individually on irradiated
human foreskin fibroblasts (HFF; ATCC CRL-2097) in KSR media con-
sisting of DMEM/nutrient mixture F-12, supplemented with non-es-
sential amino acids (NEAA) 1%, glutamine 2 mM, β-mercaptoethanol
0.1 mM, 0.5% pen/strep and 20% knockout serum replacement (all
from Thermo Fisher). For maintaining pluripotency, KSR media was
further supplemented with FGF2 (15 ng/ml; Peprotech) and Activin A
(15 ng/ml; R&D Systems). iPSCs were passaged by mechanical dissec-
tion of undifferentiated fragments, which were transferred to freshly
prepared HFF every seven days and media was changed every second
day. The absence of mycoplasma was confirmed by using the Look Out
Mycoplasma PCR Detection Kit (Cat#MP0035, Sigma).
3.2. Pluripotency markers and embryonic body formation assay
Immunocytochemistry analysis was performed by fixing iPSCs in
4% PFA at 4 °C for 10 min. Subsequently, cells were washed in PBS and
blocked for 1 h at room temperature (RT) with 5% donkey serum in PBT
(PBS with 0.25% triton-X) solution. Primary antibodies were diluted in
blocking solution and applied overnight at 4 °C followed by washes in
PBT, after which the corresponding secondary antibodies were added
for 1 h at RT (antibodies shown in Table 2). Nuclei were counterstained
with 4,6-diamidino-2-phenylindole (DAPI; 1 μg/ml, Sigma). Samples
were mounted in PVA-DABCO and visualized under an ApoTome
fluorescent microscope (ZEISS), or ZEISS LSM 780 confocal microscope
and images captured using the ZEN software (ZEISS). The percentage of
positive cells for NANOG and POU5F1 was calculated by counting cells
from three different colonies and data expressed as a percentage of
NANOG+/DAPI and POU5F1+/DAPI. Alkaline phosphatase staining
was performed following the manufacturer's procedure (Cat#00–0009,
Stemgent).
Embryoid bodies (EBs) were generated by culturing fragments of
iPSCs in suspension using ultra-low cluster 96-well plates (Corning). For
mesoderm and endoderm differentiation, fragments were cultured in
KSR media supplemented with 10 ng/ml Activin A, 1.5 µM CHIR99021
(Cat#04–0004–10, Stemgent) and 40 ng/ml BMP2 (Cat#120–02,
Peprotech) for 14 days. For neuroectoderm differentiation, fragments
were first cultured for six days on a Vitronectin-coated (STEM CELL
Technologies) 35 mm diameter Petri dish (Thermo scientific) in N2B27
medium containing 1:1 mix of Neurobasal medium and DMEM/F-12
medium, supplemented with insulin/transferrin/selenium-A 1%, N2
supplement 1%, B27 Supplement Minus Vitamin A 1%, glucose 0.3%,
penicillin 25 U/ml, and streptomycin 25 μg/ml (all from Life
Technologies) supplemented with 10 µM SB431542 (Tocris) and 0.1 µM
LDN193189 (Stemgent), then each fragment was mechanical dissected
into two and transferred to an ultra-low cluster 96-well plate for sus-
pension culture, to form neurospheres, in N2B27 media supplemented
with 20 ng/ml FGF2 for one week.
EBs and neurospheres were fixed in 4% PFA for 20 mins at 4 °C,
washed in PBS and placed in a 30% sucrose solution overnight before
being embedded in Tissue-Tek OCT compound (Labtek). For im-
munostaining, EBs and neurospheres were cut at 10 µm on a cryostat
and antibodies applied following the protocol stated above.
Table 1
Characterization and validation.
Classification Test Result Data
Morphology Photography Normal morphology Fig. 1 panel A
Phenotype Qualitative analysis by
immnuocytochemistry
Staining/expression of pluripotency markers: Alkaline
phosphatase (ALP), POU5F1, TRA1-81, NANOG, SSEA-4
Fig. 1 panel A, C, D
Quantitative analysis by
Immunocytochemistry counting
Assess% of positive cells for antigen markers. POU5F1:
98.81% ± 2.05 S.D, NANOG: 99.51% ± 0.43 S.D.
Fig. 1 panel B
Genotype Karyotype (Q-banding) and resolution 46XX, Resolution 450–500 Fig. 1 panel G
Identity STR analysis DNA Profiling Performed. 10 genomic markers 100% matched
between parental cells and iPSCs
Available with the
corresponding author
Mutation analysis (If
applicable)
Sequencing heterozygous Fig. 1 panel E
Southern Blot OR WGS N/A N/A
Microbiology and virology Mycoplasma Mycoplasma testing by RT-PCR: Negative Supplementary Figure 1
Differentiation potential Embryoid body formation Embryoid bodies express endoderm markers: SOX17/FOXA2;
mesoderm marker: BRACHYURY; ectoderm marker: PAX6/
SOX2.
Fig. 1 panel H
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Fig. 1. Characterization of the DANi-011A iPSC line generated from a Parkinson's disease patient with a LRRK2 p.G2019S mutation.
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3.3. Genomic analysis
Karyotype analysis was performed on DANi-011A passage 46 by Q-
banded metaphase spreads that were prepared according to standard
protocol at an accredited clinical laboratory. Ten metaphases were
counted, and two further analyzed in accordance with clinical stan-
dards. Briefly, fresh medium was added and supplemented with col-
cemid at 0.1 µg/ml and incubated at 37 °C for 60–120 min. Single cells
were harvested by trypsinization (0.025% W/V in Hanks buffered
saline) at 37 °C, after which the trypsinization was inactivated by
adding serum-containing medium. Cells were centrifuged and re-
suspended in a hypotonic KCl 0.56% and incubated at 37 °C for 30 min
in a water bath. After which, cells were centrifuged and resuspended in
fixation buffer (1 part acetic acid and 3 parts methanol). The cells were
again spun down by centrifugation and resuspended in fixative. This
step was repeated once. The resuspended cells were added dropwise to
glass slides, dried, stained by quinacrine and mounted for microscopy.
The G2019S variant in the patient fibroblasts and iPSCs was vali-
dated by standard PCR. Briefly, genomic DNA was collected and pur-
ified using the GeneJet Genomic DNA purification kit (Cat #K0721,
ThermoFisher Scientific). The PCR amplification was performed in a
Thermo Scientific™ Arktik™ Thermal Cycler with the following pro-
gram: initial denaturation at 94 °C for 30 s; 35 cycles of (94 °C for 30 s,
60 °C for 30 s, 68 °C for 30 s); final extension at 68 °C for 5 min and hold
at 15 °C. PCR products were extracted and purified with DNA Clean and
concentrator kit (Cat#D4005, Zymo Research) and then samples were
prepared and sent to Eurofins Genomics for Sanger sequencing using
primers in Table 2. The DANi-011A line was tested for Sendai virus
particles by staining iPSC colonies with an anti-Sendai virus antibody
(Table 2). Cell line identity was performed by the Department of Mo-
lecular Medicine (MOMA) at Aarhus University Hospital with the
GenePrint® 10 system.
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Table 2
Reagents details.
Antibodies used for immunocytochemistry/flow-citometry
Antibody Dilution Company Cat # and RRID
Pluripotency markers mouse anti-OCT3/4(C-10) 1:100 Santa Cruz Biotechnology Cat# sc-5279, RRID:AB_628,051
Pluripotency markers mouse anti-NANOG 1:100 eBioscience Cat# 14–5768–82, RRID:AB_467,572
Pluripotency markers mouse anti-TRA–1–81 1:200 Millipore Cat# MAB4381, RRID:AB_177,638
Pluripotency markers mouse anti-SSEA4 1:40 DSHB Cat# MC–813–70, RRID:AB_528,477
Differentiation markers goat anti-SOX17 1:200 R&D Systems Cat# AF1924, RRID:AB_355,060
Differentiation markers rabbit anti-FOXA2 1:500 Cell signaling Technology Cat#8186, RRID: AB_10,891,055
Differentiation markers goat anti-BRACHYURY 1:100 R&D Systems Cat# AF2085, RRID:AB_2,200,235
Differentiation markers mouse anti-PAX6 1:40 DSHB Cat# PAX6, RRID: AB_528,427
Differentiation markers goat anti-SOX2 1:100 R&D Systems Cat# AF2018, RRID:AB_355,110
Sendai virus free test rabbit anti-Sendai virus 1:500 MBL International Cat# PD029, RRID:AB_10,597,564
Secondary antibodies for IF Goat anti-mouse IgG2b Alexa 568 1:1000 ThermoFisher Scientific Cat# A21144, RRID: AB_2,535,780
Secondary antibodies for IF Goat anti-mouse IgG1 Alexa 488 1:1000 ThermoFisher Scientific Cat# A21121, RRID:AB_141,514
Secondary antibodies for IF Donkey anti-mouse IgM Alexa 488 1:200 Jackson ImmunoResearch Cat# 715–545–020, RRID:AB_2,340,844
Secondary antibodies for IF Goat anti-mouse IgG3 Alexa 594 1:200 Jackson ImmunoResearch Cat# 115–585–209, RRID: AB_2,338,889
Secondary antibodies for IF Donkey anti-goat IgG (H + L) Alexa 488 1:1000 ThermoFisher Scientific Cat# A-11,055, RRID: AB_2,534,102
Secondary antibodies for IF Donkey anti-rabbit IgG (H + L) Alexa 568 1:1000 ThermoFisher Scientific Cat# A11057, RRID: AB_2,534,104
Secondary antibodies for IF Donkey anti-mouse IgG (H + L) Alexa 568 1:1000 ThermoFisher Scientific Cat# A10037, RRID: AB_2,534,013
Primers
Target Forward/Reverse primer (5′−3′)
Targeted mutation analysis LRRK2 G2019S
Product size 518
GGCAGATACCTCCACTCAGC/ TTGATTTGCCTCACAAGTGC
Targeted mutation sequencing LRRK2 G2019S GGCAGATACCTCCACTCAGC
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